What is the 13F Pro Quality Score for LENZ?

13F Pro ranks LENZ Therapeutics, Inc. (LENZ) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LENZ's current score at https://13fpro.ai/research/LENZ (free sign-up required for the full ranking).

Which hedge funds own the most LENZ stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LENZ include RA CAPITAL MANAGEMENT, L.P., Alpha Wave Global,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LENZ as soon as new 13F filings post.

Where does 13F Pro source LENZ data?

All LENZ Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. LENZ Therapeutics, Inc. files with the SEC under CIK 1815776. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LENZ in?

LENZ Therapeutics, Inc. (LENZ) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LENZ research updated on 13F Pro?

LENZ's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LENZ Therapeutics, Inc.(LENZ)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1815776 LENZ stock profile & AI dashboard →

13F Pro Quality Score

19.6/100

Rank #2,688 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

3.1/100

Profitability

30.0/100

Balance Sheet

7.9/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

21.2/100

Revenue Scale

30.0/100

Dilution Risk

4.2/100

LENZ Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LENZ Therapeutics, Inc. (LENZ), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LENZ at 19.6/100 on a 32-signal composite quality model, placing it at rank #2,688 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (3.1) and balance sheet strength (7.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), LENZ Therapeutics, Inc. reports quarterly revenue of $1.9M, net income of $-41.5M, free cash flow of $-33.6M. Top institutional holders of LENZ by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Alpha Wave Global,, FMR, based on the most recent SEC filings. LENZ trades on the Nasdaq exchange and files with the SEC under CIK 1815776. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LENZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LENZ Therapeutics, Inc. directly from SEC EDGAR. LENZ Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 19 and 29 since 2026, currently 19.6 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about LENZ Therapeutics, Inc.

Quirks, history, and lore behind LENZ — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in California · focused on ophthalmology.
2
The Numbers
A small-cap company with no product revenue yet — the classic pre-commercial biotech burn rate — funded by capital raises to push its lead asset through late-stage trials.
3
The History
Founded in the early 2020s, it went public relatively quickly after formation, targeting a massively underserved condition affecting hundreds of millions of aging eyes worldwide.
4
The Secret
Its lead drug candidate is designed to treat presbyopia — age-related loss of near vision — using a once-daily eye drop rather than reading glasses or surgery.
5
The Lore
The company's approach builds on aceclidine chemistry, aiming to be a cleaner, more tolerable alternative to a rival drop that already won FDA approval in the same space.
6
The Giveaway
Its ticker is a four-letter word for a lens, its pipeline is literally about your eye's lens losing flexibility with age, and its lead program is called LNZ100.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.9M

Net Income

Q1 2026

$-41.5M

Free Cash Flow

Q1 2026

$-33.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$19.1MFY 2025

FY20 —FY21 —FY22 —FY25 $19.1M

Net Income

+18.7% YoY

$-82.1MFY 2025

FY20 $-68.4MFY21 $-70.8MFY22 $-101.1MFY25 $-82.1M

Operating Income

+13.7% YoY

$-91.1MFY 2025

FY20 $-13.5MFY21 $-60.4MFY22 $-105.6MFY25 $-91.1M

EPS (Diluted)

-1914.1% YoY

$-2.85FY 2025

FY20 —FY21 $-0.19FY22 $-0.14FY25 $-2.85

Total Assets

-5.0% YoY

$305.9MFY 2025

FY20 $22.6MFY21 $402.0MFY22 $321.9MFY25 $305.9M

Op. Cash Flow

+21.4% YoY

$-69.2MFY 2025

FY20 $-8.7MFY21 $-52.9MFY22 $-88.0MFY25 $-69.2M

Metric	FY 2025	FY 2022	FY 2021	FY 2020
Revenue	$19.1M	—	—	—
Net Income	$-82.1M +18.7%	$-101.1M -42.8%	$-70.8M -3.5%	$-68.4M
Operating Income	$-91.1M +13.7%	$-105.6M -74.8%	$-60.4M -347.7%	$-13.5M
EPS (Diluted)	$-2.85 -1914.1%	$-0.14 +24.9%	$-0.19	—
Total Assets	$305.9M -5.0%	$321.9M -19.9%	$402.0M +1681.5%	$22.6M
Operating Cash Flow	$-69.2M +21.4%	$-88.0M -66.5%	$-52.9M -506.0%	$-8.7M

AI Insight: LENZ Financial Trends

LENZ posted its first revenue in Q3 2025 but losses have since surged, with Q1 2026 operating loss hitting -$44M — the steepest in the dataset.

• Revenue appeared in Q3 2025 at $12M but collapsed to $2M in Q4 2025 and held flat in Q1 2026.

• Operating loss widened sharply from -$19M in Q3 2025 to -$44M in Q1 2026, a deterioration of $25M in two quarters.

• Operating cash outflow deepened to -$34M in Q1 2026, the worst in eight quarters, signaling accelerating cash burn.

• Equity rose to $284M in Q4 2025 — likely a capital raise — then declined to $246M in Q1 2026.

⚠ Revenue dropped 83% from Q3 2025's $12M to $2M; sustained commercial traction is unproven and critical to monitor.

⚠ At -$34M quarterly operating cash burn with no debt disclosed, runway duration depends entirely on equity raises.

⚠ Equity fell $38M in Q1 2026 alone; further dilutive financing appears likely if losses remain at current levels.

AI Insight: LENZ Ratio Trends

LENZ's return metrics are deteriorating sharply, with ROIC deepening to -71.6% in Q1 2026 from -24.1% in Q3 2024, signaling accelerating cash burn pre-revenue.

• ROIC worsened from -24.1% in Q3 2024 to -71.6% in Q1 2026, a 47.5pp deterioration over five quarters.

• ROA tracked similarly negative, falling from -18.2% in Q3 2024 to -60.9% in Q1 2026.

• Q3 2025 is the only quarter with OpMargin and NPM data: -151.1% and -133.6%, reflecting a pre-commercial cost structure.

⚠ ROE collapsed to -67.3% in Q1 2026 vs. -28.9% in Q2 2025 — steepest single-quarter drop in the dataset.

⚠ D/E data is entirely absent; inability to assess leverage adds meaningful uncertainty to balance-sheet risk.

⚠ TTM ROIC of -48.0% is less severe than Q1 2026's -71.6%, suggesting burn rate is accelerating intra-period.

Get alerted when LENZ's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LENZ Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LENZ

RA CAPITAL MANAGEMENT, L.P.
$38.2M4,178,823 sh
Alpha Wave Global, LP
$33.1M3,612,211 sh
FMR LLC
$32.9M3,597,784 sh
Versant Venture Management, LLC
$24.3M2,656,888 sh
BlackRock, Inc.
$18.1M1,976,823 sh
Squarepoint Ops LLC
$13.8M1,506,499 sh
abrdn plc
$10.6M1,156,161 sh
FRANKLIN RESOURCES INC
$10.1M1,100,148 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.5M1,041,188 sh
72 Investment Holdings, LLC
$9.3M1,017,751 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$38.2M	4,178,823
Alpha Wave Global, LP	$33.1M	3,612,211
FMR LLC	$32.9M	3,597,784
Versant Venture Management, LLC	$24.3M	2,656,888
BlackRock, Inc.	$18.1M	1,976,823
Squarepoint Ops LLC	$13.8M	1,506,499
abrdn plc	$10.6M	1,156,161
FRANKLIN RESOURCES INC	$10.1M	1,100,148
VANGUARD CAPITAL MANAGEMENT LLC	$9.5M	1,041,188
72 Investment Holdings, LLC	$9.3M	1,017,751

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LENZ on your watchlist

Track score changes the day LENZ Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LENZ a good stock to buy?

13F Pro's AI-powered analysis of LENZ Therapeutics, Inc. (LENZ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LENZ are available on the LENZ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LENZ?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LENZ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LENZ Therapeutics, Inc.'s investment landscape.